|
|
|
Comparison |
name |
Catalog # |
Specificity/Activity |
Type |
Brand |
Size |
Price |
|
Immobilized monoclonal antibody to human prekallikrein and kallikrein |
PK10G3-I |
|
|
Molecular Innovations |
5.0 ml |
RMB
5732 |
|
Immobilized monoclonal antibody to human prekallikrein and kallikrein |
PK10G3-I |
|
|
Molecular Innovations |
1.0 ml |
RMB
1380 |
|
Inhibitory monoclonal antibody to human prorenin, clone 4B5-E3 |
PREN4B5E3 |
|
|
Molecular Innovations |
1.0 mg |
RMB
14208 |
|
Inhibitory monoclonal antibody to human prorenin, clone 4B5-E3 |
PREN4B5E3 |
|
|
Molecular Innovations |
0.1 mg |
RMB
3539 |
|
Monoclonal antibody to human prorenin, biotin labeled |
PREN4B5E3-BIO |
|
|
Molecular Innovations |
1.0 mg |
RMB
38145 |
|
Monoclonal antibody to human prorenin, biotin labeled |
PREN4B5E3-BIO |
|
|
Molecular Innovations |
0.1 mg |
RMB
6565 |
|
Monoclonal antibody to human prorenin, clone 6E2-B7 |
PREN6E2B7 |
|
|
Molecular Innovations |
1.0 mg |
RMB
14208 |
|
Monoclonal antibody to human prorenin, clone 6E2-B7 |
PREN6E2B7 |
|
|
Molecular Innovations |
0.1 mg |
RMB
3539 |
|
Monoclonal antibody to human prorenin, FITC labeled |
PREN4B5E3-FITC |
|
|
Molecular Innovations |
1.0 mg |
RMB
38145 |
|
Monoclonal antibody to human prorenin, FITC labeled |
PREN4B5E3-FITC |
|
|
Molecular Innovations |
0.1 mg |
RMB
6565 |
|
Monoclonal antibody to human renin and prorenin, clone 7D3-E3 |
PREN7D3E3 |
|
|
Molecular Innovations |
1.0 mg |
RMB
14208 |
|
Monoclonal antibody to human renin and prorenin, clone 7D3-E3 |
PREN7D3E3 |
|
|
Molecular Innovations |
0.1 mg |
RMB
3539 |
|
Monoclonal antibody to rat prorenin, clone 2C6 |
RPREN2C6 |
|
|
Molecular Innovations |
1.0 mg |
RMB
18295 |
|
Monoclonal antibody to rat prorenin, clone 2C6 |
RPREN2C6 |
|
|
Molecular Innovations |
0.1 mg |
RMB
4123 |
|
Monoclonal antibody to rat renin and prorenin, clone 1G5 |
RPREN1G5 |
|
|
Molecular Innovations |
1.0 mg |
RMB
18295 |
|
Monoclonal antibody to rat renin and prorenin, clone 1G5 |
RPREN1G5 |
|
|
Molecular Innovations |
0.1 mg |
RMB
4123 |
|
|
|
|
|